Summary
Background Idiopathic pulmonary fibrosis (IPF) is a serious disease of the lung parenchyma. It has a known polygenetic risk, with at least seventeen regions of the genome implicated to date. Growing evidence suggests linked multimorbidity of IPF with neurodegenerative or affective disorders. However, no study so far has explicitly explored links between IPF, associated genetic risk profiles, and specific brain features.
Methods We exploited imaging and genetic data from more than 32,000 participants available through the UK Biobank population-level resource to explore links between IPF genetic risk and imaging-derived brain endophenotypes. We performed a brain-wide imaging-genetics association study between the 17 known loci of IPF genetic risk and 1,248 multi-modal imaging-derived features, which characterise brain structure and function.
Findings We identified strong associations between cortical thickness and white matter microstructure and IPF risk loci in chromosomes 17 (17q21.31) and 8 (DEPTOR). Through co-localisation analysis, we confirmed that the associated neuroimaging features and IPF share a single causal variant at the chromosome 8 locus. Exploratory post-hoc analysis suggested that forced vital capacity may act as a partial mediator in the association between the DEPTOR variant and white matter microstructure, but not between the DEPTOR risk variant and cortical thinning in the anterior cingulate.
Interpretation Our results reveal for the first time associations between IPF genetic risk and differences in brain structure, for both cortex and white matter. Differences in tissue-specific imaging signatures suggest distinct underlying mechanisms with focal cortical thinning in regions with known high DEPTOR expression unrelated to lung function, and more widespread microstructural white matter changes consistent with hypoxia or neuroinflammation with potential mediation by lung function.
Funding This study was supported by the NIHR-funded Nottingham Biomedical Research Centre and the UK Medical Research Council.
Research in context
Evidence before this study
Evidence before this study Idiopathic pulmonary fibrosis (IPF) is a condition in which the lungs become scarred (fibrosed). Although IPF primarily affects the lungs, co-occurrence of impaired brain function, such as cognitive decline, increased risk of neurodegenerative disorders, cerebrovascular accidents, depression, and anxiety have been reported. The nature of this association is unclear and no post-mortem or in-vivo investigations have been performed to explore this directly. At the genetic level, 17 regions of the genome have been found to drive the genetic risk for IPF.
Added value of this study
Added value of this study Using previously identified IPF genetic variants and neuroimaging-derived features from 32,431 participants available through the UK Biobank, we performed the first brain-wide association study for IPF risk variants. We identified brain endophenotypic associations for two IPF risk associated genetic variants, one in chromosome 17 and one in chromosome 8. In particular, increased IPF genetic risk, conferred by a variant near to the DEPTOR gene on chromosome 8, was associated with focal cingulate cortical thinning and more widespread changes in white matter microstructure. The cortical association signature was observed in regions with known DEPTOR expression while the subcortical findings may be mediated by forced vital capacity (measure of impaired lung function), hinting to distinct direct (cingulate) and indirect (subcortical) brain effects of DEPTOR risk alleles.
Implication of all the available evidence
Implication of all the available evidence The reported brain-wide IPF risk association patterns reveal two plausible mechanisms that may explain the known association of IPF and brain disorders: (i) direct and focal, thought to be related to paralimbic mTOR dysregulation and (ii) indirect and widespread, in keeping with secondary effects from impaired lung function such as hypoxia. Taken together, these data support the hypothesis that genetic risk profiles may explain some of the observed comorbidity of IPF and brain disorders.
Competing Interest Statement
RGJ reports research funding from AstraZeneca, Biogen, Galecto, GlaxoSmithKline, RedX, Pliant, and Genetech; personal fees from Bristol Myers Squibb, Daewoong, Veracyte, Resolution Therapeutics, RedX, Pliant, Chiesi, Roche, PatientMPower, AstraZeneca, GSK, Boehringer Ingelheim, Galapagos, and Vicore; non-financial support from NuMedii and Action for Pulmonary Fibrosis, outside the submitted work. LVW reports research funding from GSK and Orion Pharma and have conducted consultancy for Galapagos. DPA reports research funding from Biogen. All other authors declare no conflict of interest.
Funding Statement
This study was supported by the NIHR-funded Nottingham Biomedical Research Centre and the UK Medical Research Council.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at the UK Biobank data
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos